Lipodystrophic diabetes treated with fenfluramine.

Area of Science:

• Endocrinology
• Metabolic Disorders
• Neuroendocrinology

Background:

• Congenital generalized lipodystrophy (CGL) is a rare genetic disorder characterized by near-complete absence of adipose tissue.
• CGL is often associated with diencephalic dysfunction, impacting hypothalamic neurotransmitters.
• Patients frequently develop severe, treatment-resistant diabetes mellitus and hyperlipidemia post-puberty.

Observation:

• A 15-year-old female patient with CGL presented with severe lipodystrophic diabetes.
• Her condition included fasting hyperglycemia (>300 mg/100 ml), hyperinsulinemia with insulin resistance, and hyperlipidemia.
• She also experienced voracious hunger and profuse perspiration.

Findings:

• Daily administration of fenfluramine led to significant clinical improvement.
• Key improvements included reduced hunger and perspiration, normalization of serum lipids, and decreased blood glucose levels.
• Fenfluramine therapy also increased the patient's sensitivity to exogenous insulin and normalized urinary 5-HIAA excretion, a serotonin metabolite.

Implications:

• Fenfluramine shows promise as a therapeutic agent for managing lipodystrophic diabetes in CGL.
• The findings suggest a role for serotonergic pathways in the pathophysiology of CGL and its associated metabolic disturbances.
• This case highlights the potential of targeting hypothalamic neurotransmitters for treating complex metabolic syndromes.